The effects of octreotide in dilated cardiomyopathy: An open-label trial in 12 patients

Japanese Heart Journal

Volumn 45, Issue 4, 2004, Pages 613-621

  Eryol, Namlk Kemal ^a   Güven, Muhammed ^a   Topsakal, Ramazan ^a   Sungur, Murat ^a   Özdogru, Ibrahim ^a   Inanç, Tuǧrul ^a   Oǧuzhan, Abdurrahman ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Dilated cardiomyopathy; Octreotide

Indexed keywords

DIGOXIN; ENALAPRIL; FUROSEMIDE; ISOSORBIDE DINITRATE; OCTREOTIDE; SPIRONOLACTONE; TROPONIN T; CARDIOTONIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; AGED; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 6344285610     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.45.613     Document Type: Article

References (37)

1. Bristow MR, Bohlmeyer TJ, Gilbert EM. Dilated Cardiomyopathy. In: Alexander RW, Schlant RC, Fuster V, ed. Hurst's The Heart. New York: McGraw-Hill, 1998; 2039-55.
2. Wyne J, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald E, ed. Braunwald Heart Disease. Philadelphia: W.B. Saunders Company, 1997; 1404-34.
3. Houck WV, Pan LC, Kribbs SB, et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 1999; 100: 2003-9.
4. Giustina A, Volterrani M, Manelli F, et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J 1999; 137: 1035-43.
5. Genth-Zotz S, Zotz R, Geil S, Voigtlander T, Meyer J, Darius H. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 1999; 99: 18-21.
6. Lamberts AWJ, van der Lely AJ, De Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
7. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113: 921-5.
8. Nishiki M, Murakami Y, Sohmiya M, et al. Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide. Endocr J 1997; 44: 655-60.
9. Shimakura A, Miyakoshi H, Ohkuwa H, et al. Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure. Jpn Heart J 2002; 43: 69-77.
10. von den Heuvel PACMB, Elbers HRJ, Plokker HWM, Bruschke AVG. Myocardial involvement in acromegaly. Int J Cardiol 1984; 6: 550-3.
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
12. Taylor R, Waggoner AD. Doppler assessment of left ventricular diastolic function: a review. J Am Soc Echocardiogr 1992; 5: 603-12.
13. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
14. Epstein FH, Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85.
15. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341: 1276-83.
16. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999; 138: 646-53.
17. Fazio S, Palmieri EA, Biondi B, Cittadini A, Sacca L. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence. Eur J Endocrinol 2000; 142: 211-6.
18. Jenkins RC, Ross RJM. The growth hormone IGF-I axis in dilated cardiomyopathy. Clin Endocrinol 1999; 50: 415-6.
19. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P. Edema of cardiac origin: Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989; 80: 299-305.
20. Broglio F, Fubini A, Morello M, et al. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol 1999; 50: 417-30.
21. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endoc Rev 1994; 15: 555-73.
22. Rettig R, Geist R, Sauer U, Rohmeiss P, Unger T. Central effects of somatostatin: pressor response, AVP release, and sympathoinhibition. Am J Physiol 1989; 257: R588-94.
23. Campbell G, Gibbins IL, Morris JL, et al. Somatostatin is contained in and released from cholinergic nerves in the heart of the toad Bufo marinus. Neuroscience 1982; 7: 2013-23.
24. Day SM, Gu J, Polak JM, Bloom SR. Somatostatin in the human heart and comparison with guinea pig and rat heart. Br Heart J 1985; 53: 153-7.
25. Hirai S, Hasegawa J, Mashiba H. Positive inotropic effect of somatostatin in guinea-pig ventricular muscles. J Mol Cell Cardiol 1989; 21: 607-16.
26. Du XY, Schoemaker RG, Bos E, Saxena PR. Different pharmacological responses of atrium and ventricle: studies with human cardiac tissue. Eur J Pharmacol 1994; 259: 173-80.
27. Xu Y, Lu L, Zhu P, Schwartz GG. Beta-adrenergic stimulation induces transient imbalance between myocardial substrate uptake and metabolism in vivo. Am J Physiol 1998; 275: H2181-90.
28. Lombardi G, Colao A, Ferone D, et al. Cardiovascular aspects in acromegaly: Effects of treatment. Metabolism 1996; 45 (suppl 1): 57-60.
29. Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 1998; 98: 2404-14.
30. Lin CI, Su MT, Luk HN, Wu HL. Suppressive effects of somatostatin in dog Purkinje fibres. Br J Pharmacol 1988; 93: 192-8.
31. Tyden G, Samnegaard H, Thulin L, et al. Circulatory effects of somatostatin in anaesthetized man. Acta Chir Scand 1979; 145: 443-6.
32. Sieber C, Gnadinger M, del Pozo E, Shaw S, Weidmann P. Effect of a new somatostatin analogue SMS 201-995 (sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988; 28: 25-32.
33. Wang SS, Lee FY, Wu SL, et al. Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997; 26: 1128-34.
34. Jonassen TE, Christensen S, Sorensen AM, et al. Effects of chronic octreotide treatment on renal changes during cirrhosis in rats. Hepatology 1999; 29: 1387-95.
35. Mountokalakis T, Levy M. Effect of a selective octapeptide analogue of somatostatin on renal water excretion in the dog. Metabolism 1985; 34: 408-9.
36. Padayatty S, Perrins EJ, Belchetz PE. Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 1996; 134: 554-9.
37. Sakamoto H. Cardiovascular effects of octreotide, a long-acting somatostatin analog. Cardiovasc Drug Rev 1999; 17: 358-73.